Table 2.
Demographic and clinical characteristics of the patients based on the outcome of the antifungal prophylaxis
| Total (n = 85) (%) | Success (n = 40) (%) | Failure (n = 45) (%) | p value | |
|---|---|---|---|---|
| Relapsing or refractory acute myeloid leukemia | 39 (45.9) | 11 (27.5) | 28 (62.2) | 0.001 |
| Duration of neutropenia median (Interquartile range) days | 26 (16.5–35.5) | 20.5 (15–31.5) | 29 (21–42) | 0.003 |
| Neutropenia longer than 21 days | 52 (61.2) | 18 (45.0) | 34 (75.6) | 0.004 |
| Type of antifungal prophylaxis | 0.01 | |||
| Posaconazole | 56 (65.9) | 32 (80.0) | 24 (53.3) | |
| Fluconazole | 29 (34.1) | 8 (20.0) | 21 (46.7) | |
| Duration of antifungal prophylaxis, Median (Interquartile range) days | 21 (15–27) | 22 (20–27.5) | 17 (13–27) | 0.026 |
| Overall mortality | 16 (18.8) | 1 (2.5) | 15 (33.3) | <0.001 |